Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript

Core Insights - The conference call focuses on the top line results from Part B of the Phase Ib clinical trial evaluating TX45 for patients with pulmonary hypertension associated with reduced ejection fraction heart failure (PH-HFrEF) [2][3] Group 1: Clinical Trial Overview - The clinical trial involved 14 patients and aimed to assess the safety and tolerability of TX45 in the PH-HFrEF patient population [3] - The trial also sought to explore the hemodynamic effects of TX45, with expectations of observing effects similar to previous studies [3]